ReviewFrontiers in oncology2025
Post-translational modifications of protein and lung cancer.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- N-glycosylation of ERLIN2 promotes hepatocellular carcinoma progression by enhancing CCNB1 stability.Molecular and cellular biochemistry · 2026Article
- Exon-skipping antisense oligonucleotides targeting SUMO1 and SUMO2 demonstrate chemosensitizing effects in NSCLC cells in tissue culture.Research square · 2026Article
- TRIM47: molecular characteristics, disease-related mechanisms, and clinical translational value.Frontiers in immunology · 2026Review
- Research progress of OTUD7B: from structural function and disease mechanisms to clinical translation.Frontiers in immunology · 2026Review
- The impact of obesity-related systemic inflammation on the efficacy, toxicity, and biomarkers of immune checkpoint inhibitors in lung cancer: from mechanisms to clinical management.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Post-translational modifications (PTMs) represent a pivotal regulatory mechanism in cellular processes, wherein the addition or removal of specific functional groups to amino acid residues dynamically modulates protein activity, subcellular localization, expression levels, and interactions with other biomolecules. Key PTMs, including phosphorylation, acetylation, methylation, glycosylation, ubiquitination, and emerging types like succinylation and crotonylation, exponentially diversify the proteome's functional landscape. In lung cancer, PTMs orchestrate critical pathological processes, such as EGFR phosphorylation-driven proliferation, H3K27me3-mediated epigenetic silencing, and KEAP1 succinylation-regulated redox homeostasis. Recent advances in mass spectrometry (MS), phosphoproteomics, and epigenomic profiling have enabled systematic mapping of PTM networks, revealing their potential as diagnostic biomarkers, therapeutic targets, and predictors of drug response. This review synthesizes the mechanistic roles of PTMs in lung cancer pathogenesis and their translational applications, highlighting multi-omics integration and PTM-targeted therapies as future frontiers in precision oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.